Advertisement
Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Amgen Announces Positive Data for Cholesterol-Lowering Medication

October 2, 2014 2:12 pm | News | Comments

Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH). Read more...

Takeda Announces Phase 3 Data for UC, Crohn's Drug

October 2, 2014 10:29 am | News | Comments

Takeda announced that new data from GEMINI LTS, a Phase 3, ongoing, open-label extension study of Entyvio (vedolizumab) for the treatment of adults with moderately to severely active UC and CD will be presented as oral presentations during the 21st United European Gastroenterology Week in Vienna, Austria. Read more...

Japan Starts World-First Stem Cell Trial, Plans More

October 2, 2014 10:20 am | by Cynthia Fox, Science Editor | Articles | Comments

The first patient has been treated, by Japan’s Riken Institute, in the world’s first clinical study of stem cells made from ordinary mature cells. The cells were retinal pigment epithelial (RPE) cells, but they began as a macular-degeneration patient’s skin cells.

Advertisement

High-Cholesterol Drug Data Lifts Esperion

October 2, 2014 10:13 am | News | Comments

Shares of Esperion Therapeutics surged in aftermarket trading after the company reported positive clinical trial results for its experimental high-cholesterol drug ETC-1002. Read more...                   

Discovery Helps to Spot What Makes a Good Drug

October 2, 2014 10:03 am | News | Comments

A new test developed by researchers from The University of Manchester could revolutionize the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. Read more...

New Type of Clinic Eyed to Help Stop Ebola

October 2, 2014 9:45 am | by Maria Cheng and Sarah Dilorenzo | News | Comments

Britain and Sierra Leone are appealing for more help to slow the biggest ever Ebola outbreak - and are proposing a new type of clinic to do that. At a London conference, officials are expected to announce plans to build up to 1,000 makeshift Ebola clinics in Sierra Leone.  Read more...

Drugmaker Submits Harder-to-Abuse Zohydro to FDA

October 2, 2014 9:33 am | by Matthew Perrone, AP Health Writer | News | Comments

The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring. Read more...          

New Drug-Delivery Capsule May Replace Injections

October 1, 2014 4:15 pm | News | Comments

Researchers have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. Read more...                      

Advertisement

‘Stealth’ Nanoparticles Could Improve Cancer Vaccines

October 1, 2014 4:05 pm | News | Comments

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. Read more...

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

October 1, 2014 3:59 pm | News | Comments

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to new research. Read more...

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:52 pm | News | Comments

Drugmaker Merck said that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Read more...     

Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Data

October 1, 2014 3:45 pm | News | Comments

Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Read more...

Ebola Treatment Makers Rise After First U.S. Case

October 1, 2014 3:29 pm | News | Comments

Shares of several drugmakers developing potential vaccines or treatments for the deadly Ebola virus rose in premarket trading, continuing a run that started after federal officials confirmed that the first case of the disease has been diagnosed in the United States. Read more... 

Advertisement

Have Our Bodies Held the Key to New Antibiotics All Along?

October 1, 2014 11:53 am | News | Comments

As the threat of antibiotic resistance grows, scientists are turning to the human body and the trillion or so bacteria that have colonized us— collectively called our microbiota— for new clues to fighting microbial infections. Read more...    

Immunovaccine Announces Plans for Phase 2 Clinical Trial of DPX-Survivac

October 1, 2014 11:14 am | News | Comments

Immunovaccine Inc. (“Immunovaccine” or “IMV”), a clinical stage vaccine and immunotherapy company, provided a clinical development program update for DPX-Survivac, the company’s lead cancer vaccine candidate. Read more...

Drug and Device Firms Paid $3.5B to Care Providers

October 1, 2014 10:34 am | by Ricardo Alonso-Zaldivar | News | Comments

From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed in a new effort to spotlight potential ethical conflicts in medicine. Read more...

Targeted Treatment Could Halt Womb Cancer Growth

October 1, 2014 10:06 am | News | Comments

A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer. Read more...

Early Antibiotic Use Linked to Childhood Obesity Risk

September 30, 2014 3:16 pm | News | Comments

The use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood. Read more...                         

Scientists Engineer Antibiotics in Race Against Drug Resistance

September 30, 2014 2:56 pm | News | Comments

We face an urgent global health problem because scientists are not developing new antibiotics as fast as bacteria are developing antibiotic resistance. But new research from UCLA has made important progress toward solving this problem. Read more...

Engineers Devise Technology for Rapidly Testing Drug-Delivery Vehicles

September 30, 2014 2:43 pm | News | Comments

Engineers have devised a way to rapidly test hundreds of different drug-delivery vehicles in living animals, making it easier to discover promising new ways to deliver a class of drugs called biologics, which includes antibodies, peptides, RNA, and DNA, to human patients. Read more...

Testing Cancer Drugs' Benefit for Individual Patients

September 30, 2014 2:28 pm | News | Comments

An official at a life sciences startup based on a Purdue University innovation says his company may help oncologists see faster than ever which drug therapies will benefit cancer patients and to what extent. Read more...         

Viagra Ads Target Women for First Time

September 30, 2014 1:52 pm | by Linda Johnson, AP Business Writer | News | Comments

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women. Read more...

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | News | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

Pfizer, Kyowa Hakko Kirin Partner on Immuno-Oncology Combo Study

September 30, 2014 10:49 am | News | Comments

Pfizer Inc. and Kyowa Hakko Kirin announced that they've entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read more...         

NIH Awards Seven New Vaccine Adjuvant Discovery Contracts

September 30, 2014 10:37 am | News | Comments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading